Long-term safety of pirtobrutinib in people with chronic lymphocytic leukemia
Studies long-term safety of pirtobrutinib in adults with previously treated leukemia or lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Key facts
- Where
- Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou, Tianjin, Ürümqi, Xuzhou, and Zhengzhou, ChinaSee the 13 sites
- Phase
- Phase 4
Where in China
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaNot yet recruiting
- Hunan Cancer HospitalChangsha, ChinaNot yet recruiting
- Sun Yat-Sen University Cancer CenterGuangdong, ChinaTaking people
- Nanfang Hospital of Southern Medical UniversityGuangzhou, ChinaTaking people
- Gansu Provincial Cancer HospitalLanzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaTaking people
- Fudan University Shanghai Cancer CenterShanghai, ChinaNot yet recruiting
- Taizhou Hospital of Zhejiang ProvinceTaizhou, ChinaTaking people
- Hematology Hospital of the Chinese Academy of Medical SciencesTianjin, ChinaTaking people
- Tianjin Medical University Cancer Institute & HospitalTianjin, ChinaTaking people
- Affiliated Cancer Hospital of Xinjiang Medical UniversityÜrümqi, ChinaNot yet recruiting
- The Affiliated Hospital of Xuzhou Medical CollegeXuzhou, ChinaTaking people
- Henan Cancer HospitalZhengzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07218341
- Record updated
- 4 November 2026
- Original description
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.Read full original descriptionShow less
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Inclusion: Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020.
Exclusion: This is not applicable to this study.